A Phase 3 interventional study of Reconyl and Placebo of Reconyl in Cough, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a 2-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing Reconyl at a dose of 225 mg three times daily and Reconyl Placebo three times daily for a 7-day course of therapy.
Reconyl is a combination of four Indonesian herbals, Vitex trifolia folium, Zingiber officinale rhizome, Abrus precatorius folium, and Phaleria macrocarpa fructus, which have been traditionally used in treating cough and common cold. A combination of these herbals is expected to relieve cough and soothe throat, provide a promising cough treatment which has no side effects.
There will be 2 groups of treatment; each group will consist of 72 subjects with the treatment regimens for 7 days:
Treatment I : 1 tablet of Reconyl 225 mg three times daily; Treatment II : 1 tablet of Reconyl Placebo three times daily.
Subjects will be asked to come to the clinic at Baseline and at Visit 1 (Day 7) for evaluation of treatment efficacy. During the 7-day study period, subjects should record product consumption, any adverse events, and their daily VAS score in the provided Patient's Diary.
The safety profile of study medication other than vital signs and adverse event will be measured at Baseline and End of Study.
429 studies on the registry are indexed under Cough; 69 are open to participants now.
This study's enrollment of 144 is above the median of 80 across 321 interventional studies indexed under Cough.
Browse Cough studies →Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 tablet of Reconyl 225 mg three times daily
Drug: Reconyl
1 tablet of Reconyl Placebo three times daily
Drug: Placebo of Reconyl
Reconyl will be given 1 tablet three times daily as the Investigational Product.
Also known as: Herbakof
Placebo of Reconyl will be given 1 tablet three times daily as the Placebo Comparator.
Changes of VAS Score on Cough
Changes of VAS Score on Cough from Baseline to Day 7 of study treatment.
Time frame: 7 days
Changes of LCQ-acute score on Cough
Changes of LCQ-acute score on Cough from Baseline to Day 7 of study treatment.
Time frame: 7 days
Renal function (Serum creatinine and eGFR)
Concentration of serum creatinine and eGFR at Baseline and at the End of study
Time frame: 7 days
Liver function (ALT and AST)
Concentration of aspartate transaminase (AST) to alanine transaminase (ALT) at Baseline and at the End of study
Time frame: 7 days
Adverse events
Adverse event, will be observed throughout the study conduct
Time frame: 7 days
Ran from Jun 2025 to primary completion in Oct 2025, 3 months.
Of 18 phase 3 interventional studies under Cough, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 3 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.